Unknown Author
January 24, 2026
Latham & Watkins Advises ChemoCentryx in its US$3.7 Billion Acquisition by Amgen
1 min
AI-made summary
- Amgen has entered into a definitive agreement to acquire ChemoCentryx, Inc., a biopharmaceutical company specializing in orally administered therapeutics for autoimmune diseases, inflammatory disorders, and cancer, for US$52 per share in cash, valuing the transaction at approximately US$3.7 billion
- Latham & Watkins LLP is representing ChemoCentryx in the deal, with a team providing legal advice on corporate, benefits, tax, antitrust, intellectual property, and healthcare regulatory matters.
Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, have announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for US$52 per share in cash, representing an enterprise value of approximately US$3.7 billion. Latham & Watkins LLP represents ChemoCentryx in the transaction with a corporate deal team led by Orange County partner Scott Shean, San Diego partner Michael Sullivan, and Bay Area partner Bret Stancil, with Orange County associates Shannon Cheng and Caitlin Nguyen and San Diego associate Brian Daley. Advice was also provided on benefits and compensation matters by San Diego partner Holly Bauer, with Los Angeles associate Vanessa King; on tax matters by Century City partner Sam Weiner, with Century City associate Brian Rogers; on antitrust matters by San Diego partner Hanno Kaiser and Bay Area counsel Jason Daniels; on intellectual property matters by Bay Area partner Chris Hazuka, with San Diego associate Robert Yeh; and on healthcare regulatory matters by Washington, D.C. partner Elizabeth Richards, Paris partner Eveline Van Keymeulen, and Bay Area partner Heather Deixler, with Paris associate Jeanne Fabre.~~
Article Author
Unknown Author
The Sponsor